Bright White Light Therapy Promising for Bipolar Depression

Share this content:
Bright White Light Therapy Promising for Bipolar Depression
Bright White Light Therapy Promising for Bipolar Depression

MONDAY, Oct. 16, 2017 (HealthDay News) -- Midday bright light therapy may be effective for treating bipolar depression, according to a study published online Oct. 3 in The American Journal of Psychiatry.

Dorothy K. Sit, M.D., from Northwestern University in Chicago, and colleagues randomly assigned participants (depressed adults with bipolar I or II disorder who were receiving stable dosages of antimanic medication) to treatment with either 7,000-lux bright white light or 50-lux dim red placebo light (23 participants in each group). They received daily treatment at midday for six weeks, and symptoms were assessed weekly.

The researchers found that the group treated with bright white light experienced a significantly higher remission rate than the placebo light group (68.2 versus 22.2 percent; adjusted odds ratio, 12.6) during weeks 4 to 6. The bright white light group also had significantly lower depression scores at the endpoint visit. There were no mood polarity switches. Sleep quality improved and was similar in both groups.

"The data from this study provide robust evidence that supports the efficacy of midday bright light therapy for bipolar depression," conclude the authors.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Global Prevalence of Insufficient Activity 27.5 Percent

Global Prevalence of Insufficient Activity 27.5 Percent

Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries

HTN Tx Intensification Common Upon Discharge in U.S. Vets

HTN Tx Intensification Common Upon Discharge in U.S. ...

Fourteen percent of older adults admitted to hospital for non-cardiac conditions had intensification of tx

Quarterly Canakinumab Reduces Risk for Gout Attacks

Quarterly Canakinumab Reduces Risk for Gout Attacks

Doesn't affect serum uric acid levels over time, but targets interleukin-1β

is free, fast, and customized just for you!




Already a member?

Sign In Now »